postoperatively, p[0.004). Age [-0.11, p<0.001], global preoperative GFR [-0.73, p< 0.001] and GFR of removed kidney [0.56, p<0.001] were independent predictors of percent functional compensation.
INTRODUCTION AND OBJECTIVES: Replacement of healthy renal parenchyma by renal cell carcinoma (RCC) can contribute to preexisting CKD and thus complicate management. However the magnitude and factors associated with this phenomenon have not been described.
METHODS: A retrospective review was performed of all radical nephrectomies (RN) performed at our center from 2006-2016. 155 patients with available nuclear renal scan and imaging demonstrating a single RCC tumor with normal contralateral kidney were included for analysis. Healthy renal parenchyma of each kidney and tumor volumes were measured by free-hand scripting from axial images at 3 mm intervals. Parenchymal volume discordance (volume ipsilateral kidney e volume contralateral kidney) was calculated assuming that the volume of the contralateral kidney serves as a control to assess replacement of healthy parenchyma by RCC. Split renal function was used as an internal control for volumetric measures. Multiple regression was used to identify preoperative and pathological factors related to parenchymal volume discordance.
RESULTS: Median age was 66 years and 69% of patients were male. Comorbidities included hypertension in 71%, cardiovascular disease in 27%, diabetes in 30%, and active/former smoker in 60%. Preexisting CKD was found in 34% of patients and the median estimated preoperative GFR was 29ml/min/1.73m2 in the involved kidney and 39ml/min/1.73m2 in the contralateral kidney. Median R.E.N.A.L. score was 10 and volume of the tumor, ipsilateral parenchyma and contralateral parenchyma were 111, 147 and 179 cm3 respectively. Locally advanced (!T3a) tumors were found in 61% and clear cell histology in 73% of cases. Half of the patients had a volume discordance ! 26 cm3 and a quarter !53 cm3 which represents 16% and 32% of renal parenchyma replacement by tumor, respectively. Factors independently associated with this parenchymal volume discordance were tumor volume (-0.31 p[<0.01), T stage (-0.21 p[0.02) and endophytic properties (-0.20, p[0.01) . Linear correlation was confirmed among parenchymal volumetric measures and split renal function (p[0.01).
CONCLUSIONS: Substantial replacement of healthy parenchyma by RCC occurs in the majority of patients requiring RN and is mainly driven by tumor characteristics such as endophytic location, tumor volume and T stage. 
INTRODUCTION AND OBJECTIVES:
The optimal surgical management for bilateral synchronous solid renal masses is controversial, particularly regarding the performance of bilateral partial nephrectomy (PNx) in a single setting. We evaluated the impact of simultaneous vs staged bilateral PNx on renal function, complication rates, and survival outcomes using a large institutional cohort.
METHODS: We retrospectively reviewed our institutional nephrectomy registry to identify 107 patients with non-metastatic bilateral synchronous solid renal masses managed with simultaneous or staged bilateral PNx performed within 6 months of each other between 1980 and 2015. Following the simultaneous or second staged surgery, short-term and long-term renal function changes were assessed at 3 and 12 months, respectively. Peri-operative outcomes were pooled across the staged surgeries by taking the sum of each outcome. Renal functional, peri-operative, and oncologic outcomes were compared by surgical approach.
RESULTS: Among the 107 patients studied, 77 (72%) underwent simultaneous and 30 (28%) underwent staged PNx. Median follow-up among survivors was 9.2 (IQR 5.6-13.1) years, during which time 34 died, including 10 from RCC. At diagnosis, mean age was 60 years, mean eGFR was 68 ml/min, and mean largest tumor size was 5.3 cm. There were no significant differences in clinicopathologic features between groups apart from lower BMI (mean 29 vs 32, p[0.022) in patients managed with simultaneous vs staged approach. Patients treated with a simultaneous approach had lower short-term (6% vs 24%, p[0.015) and long-term (4% vs 22%, p<0.001) reduction in eGFR. The only differences in peri-operative outcomes between simultaneous PNx and pooled rates from first and second staged PNx were lower length of stay (median 6 vs 8 days, p<0.001), lower rate of urine leak (3% vs 17%, p[0.018), and lower rate of high (Clavien 3 or 4) complications (8% vs 23%, p[0.044), respectively (Table 1 ). There were no significant differences in local recurrence, distant metastases, death from RCC, or death from any cause between groups. CONCLUSIONS: Our results suggest that when technically feasible, simultaneous bilateral PNx offers favorable outcomes vs staged PNx, and is a reasonable treatment option for patients presenting with bilateral synchronous solid renal masses.
